Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

IBD Market Snapshot: Changes Ahead, But Current Biologics Are Formidable Competitors

Zeposia Adds A Second Oral Advanced Therapy

Executive Summary

The ulcerative colitis and Crohn’s disease landscapes may shift soon but new drugs will compete with entrenched blockbusters, including Humira, Stelara and Entyvio, with biosimilars on the way.

You may also be interested in...



Prometheus Phase II Data For Novel TL1A Inhibitor Impresses On Efficacy

The company plans to move PRA023 forward into Phase III studies based on positive Phase II safety and efficacy data in UC and Crohn's disease, positioning Prometheus in a race with Roivant.

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: a market snapshot of inflammatory bowel disease; will biotech bounce back in 2023?; Phase III miss for Roche’s Alzheimer’s candidate; how Japan’s top firms did in the quarter; and China showcase hints at policies and strategies.

Takeda Raises Full-Year, Entyvio Forecasts On Solid H1

While it is benefiting handsomely from the near 50-year low of the yen, Takeda said strong underlying growth for its mainstays in the fiscal first half was one factor behind its raised full-year forecast, and the Japanese major also sees a brighter long-term outlook for global blockbuster Entyvio.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC147339

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel